[2021] Antiplatelet Drugs Market Size Is Estimated to reach US$ 2.9 Billion By 2026 Coherent Marke – PharmiWeb.com

SEATTLE, April 12, 2021, (PHARMIWEB) Global Antiplatelet Drugs Market

Antiplatelet drugs are prescribed to individuals with a history of heart attacks, and these drugs aid in reducing the chances of a recurrence of heart attacks. Some of the common antiplatelet medications include aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), only in the absence of hypersensitivity. It is prescribed along with one of the most widely known oral antiplatelet agents, including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed to patients suffering from ACS, as well as to those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.

The global antiplatelet drugs market was valued atUS$ 1.5 billionin 2017 and is expected to witness a CAGR of 7.6%over the forecast period (2018-2026).

To learn more about this report, request a sample copy* * The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2190

Rising incidence of cardiovascular diseases to drive market growth

Increasing prevalence of cardiovascular disorders, growing geriatric population, and sedentary lifestyles are some of the pivotal factors driving the global antiplatelet drugs market growth. Cardiovascular diseases are the principal cause of death in the developed and emerging economies. According to a report released by the Centers for Disease Control and Prevention (CDC) in 2015, around 800,000 people in the U.S. die annually due to stroke and other cardiovascular diseases. Some of the common cardiovascular diseases include rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease.

Global Antiplatelet Drugs Market Restraints

Limitations in efficacy, safety, and tolerability of some particular antiplatelet drugs have precluded their use in patients. For instance, antiplatelet drugs can irritate lining of the stomach that leads to gastrointestinal side effects such as indigestion and stomach aches.

Moreover, patients using these drugs can be more prone to nosebleeds, bruising or bleeding for longer than usual since they reduce the ability of the blood to clot. According to the Journal of Clinical Gastroenterology 2011 report, most spontaneous bleeding in patients treated with antiplatelet drugs occurs in the gastrointestinal tract, with an incidence of 2-3% with dual antiplatelet therapy. Moreover, failure to take antiplatelet drugs as prescribed can possess an increased risk of thrombotic complications, owing to rebound platelet activation. All these factors are expected to hinder the global market growth during the forecast timeframe.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/antiplatelet-drugs-market-to-surpass-us-29-billion-by-2026-1134

Global Antiplatelet Drugs Market Regional Analysis

North America and Europe are expected to experience significant market growth by 2026, with cardiovascular diseases being the principal cause of death in these regions. According to a 2014 study published in the European Heart Journal, Coronary Heart Diseases (CHD), particularly Myocardial Infarction (MI), are account for around 1.8 million deaths in Europe each year.

Increasing prevalence of cardiovascular diseases in Asia Pacific is expected to fuel the antiplatelet market growth in the region. According to the American Heart Association, in 2011, 17,050 deaths among Asian and Pacific Islanders were due to cardiovascular diseases; 7,828 due to coronary heart disease; and 2,476 due to myocardial infarction.

However, according to the American Heart Journal 2015 data, people in Asia Pacific are susceptible to antithrombotics or fibrinolytics and to be associated with a higher bleeding risk during management of ischemic heart diseases and antithrombotic therapy. For instance, excessive bleeding risk with standard doses of new P2Y12 inhibitors is observed in patients in Asia Pacific, especially in its eastern region. According to the Circulation Journal 2014 report, for Prasugrel, a lower maintenance dose of 3.75 mg daily was used in clinical studies and approved for Japanese patients. The lower body weight of patients in Asia Pacific, fixed dose regimen of most antiplatelet drugs, and different genetic backgrounds are the potential factors responsible for increased risk of bleeding. Therefore, bleeding is viewed as a primary concern for selecting antiplatelet drugs for patients in Asia Pacific.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2190

Global Antiplatelet Drugs Market Competitive Landscape

The key players operating in the global antiplatelet drugs market include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. These manufactures are highly focused on targeting either surface receptors or enzymes in platelets in order to protect against unwanted clot formation, following initial platelet activation.

Table of Contents

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Email:sales@coherentmarketinsights.com United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050-5539-1737 India: +91-848-285-0837

Go here to read the rest:
[2021] Antiplatelet Drugs Market Size Is Estimated to reach US$ 2.9 Billion By 2026 Coherent Marke - PharmiWeb.com